13 results
Thumbnail

D1.102 - Md

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)

Thumbnail

D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

Thumbnail

- D3.114 - Does severe asthma exist in preschool children?

Thumbnail

- D3.116 - Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis

Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Thumbnail

- D3.119 - Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype

Thumbnail

- D3.123 - Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study